|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since MIP-NPs target the site responsible for adhesion, they were more potent than commercially available therapeutic antibodies for inhibiting cell-cell adhesion in cell aggregation assays, and for completely disrupting three-dimensional tumor spheroids as well as inhibiting invasion of HeLa cells.
|
31659849 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> Oncoscan MIP array was used to analyze the patterns of CNAs on formalin fixed paraffin embedded(FFPE) tumor specimens from 163 consecutive stage I-III resected LUAD patients, 145 out of which received platinum-based adjuvant chemotherapy.
|
31448219 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we investigated the potential pro-metastatic role of Lim1 in advanced CCC (1) in vitro using a panel of CCC cell lines expressing or not the von Hippel-Lindau (VHL) tumor suppressor gene either naturally or by gene transfer and (2) ex vivo in 30 CCC metastatic tissues, including lymph nodes, lung, skin, bone, and adrenal metastases, and (3) in vivo, using a metastatic model by intravenous injection of siRNA-transfected cells into Balb/c nude.
|
30076415 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
INCB040093 inhibits the production of macrophage-inflammatory protein-1<i>β</i> (MIP-1beta) and tumor necrosis factor-<i>β</i> (TNF-beta) from a B cell line, suggesting a potential effect on the tumor microenvironment.
|
29127109 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The first dose of RLT with <sup>131</sup>I-MIP-1095 presented with low side effects and could significantly reduce the tumor burden in a majority of patients.
|
28280855 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum VEGF and urinary IL-1ra, IL-4, IL-10, GM-CSF, IP-10, MIP-1a and MIP-1b concentrations were found significantly higher in concentration in high-grade tumours compared to low-grade tumours.
|
28378639 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The MIP SNP array profiles also contributed to the diagnosis of two difficult SMARCB1-negative tumors as choroid plexus carcinoma and cribriform neuroepithelial tumor (CRINET), respectively.
|
24478045 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More importantly, in nude mice bearing human CCC tumors, Lim1 silencing abolished tumor growth through the same mechanism as in vitro.
|
21132009 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, these MIP-3alpha- and MIP-1alpha-mobilized DC precursors could be prepared for a DC vaccine capable of eliciting CTL responses to tumor cells, leading to tumor rejection in vitro and in vivo.
|
18791167 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Macrophage inflammatory protein-1alpha (MIP-1alpha), an osteoclast (OCL) stimulatory factor produced by primary multiple myeloma (MM) cells, increases bone destruction and tumor burden in murine models of MM.
|
15730850 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MIP-1alpha-mobilized DC precursors matured by treatment with granulocyte-macrophage colony-stimulating factor, interleukin 4, and tumor necrosis factor-alpha and pulsed with B16 melanoma lysates were assayed for their ability to confer protective immunity against tumor challenge in vivo and to induce cytotoxic T lymphocytes against B16 tumor cells in vitro.
|
14759987 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the human CC chemokine, macrophage inflammatory protein 3alpha (MIP-3alpha), is chemotactic for DCs in vitro, we hypothesized that adenovirus-mediated gene transfer of MIP-3alpha (AdMIP-3alpha) to tumors might induce local accumulation of DCs and inhibit growth of preexisting tumors.
|
10811846 |
2000 |